Flavokawain C

Synonyms: 卡瓦胡椒素C
Flavokawain C 是一种具有口服活性的天然查尔酮,可抑制多种癌细胞的增殖,并通过上调癌细胞中的 GADD153、抑制 Akt 和 JNK 的磷酸化、抑制早期 ERK 磷酸化、激活晚期 ERK 磷酸化、激活 caspase 相关亚型、诱导 PARP-1 裂解、诱导 p21 和 p27 上调、突变型 p53 下调以及抗凋亡 IAP 蛋白下调、提高细胞内 ROS 水平、降低 SOD 活性来诱导凋亡 (apoptosis),同时下调 FABP4、诱导癌细胞自噬 (autophagy) 并激活 AMPK/mTOR 通路,降低糖酵解相关蛋白 GLUT1 和 HK2 的表达以抑制鼻咽癌细胞的糖酵解过程,抑制 EGFR/PI3K/Akt/mTOR 信号通路的激活并降低 HSP90B1 的表达,通过降低人脐静脉内皮细胞中血管生成蛋白 Ang-1 和 VEGF 的表达来抑制血管生成,提高细胞中 γ-H2AX 水平并抑制细胞中 FAK、PI3K 及 AKT 的磷酸化以诱导细胞发生 DNA 损伤,在多个肿瘤异种移植小鼠模型中发挥抗肿瘤活性,可用于结直肠癌、结肠腺癌、肾母细胞瘤、鼻咽癌及肝癌的相关研究。
产品编号: MS-W92026 纯度: 99.53% CAS No.: 37308-75-1 分子式: C17H16O5 分子量: 300.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

Flavokawain C 是一种具有口服活性的天然查尔酮,可抑制多种癌细胞的增殖,并通过上调癌细胞中的 GADD153、抑制 Akt 和 JNK 的磷酸化、抑制早期 ERK 磷酸化、激活晚期 ERK 磷酸化、激活 caspase 相关亚型、诱导 PARP-1 裂解、诱导 p21 和 p27 上调、突变型 p53 下调以及抗凋亡 IAP 蛋白下调、提高细胞内 ROS 水平、降低 SOD 活性来诱导凋亡 (apoptosis),同时下调 FABP4、诱导癌细胞自噬 (autophagy) 并激活 AMPK/mTOR 通路,降低糖酵解相关蛋白 GLUT1 和 HK2 的表达以抑制鼻咽癌细胞的糖酵解过程,抑制 EGFR/PI3K/Akt/mTOR 信号通路的激活并降低 HSP90B1 的表达,通过降低人脐静脉内皮细胞中血管生成蛋白 Ang-1 和 VEGF 的表达来抑制血管生成,提高细胞中 γ-H2AX 水平并抑制细胞中 FAK、PI3K 及 AKT 的磷酸化以诱导细胞发生 DNA 损伤,在多个肿瘤异种移植小鼠模型中发挥抗肿瘤活性,可用于结直肠癌、结肠腺癌、肾母细胞瘤、鼻咽癌及肝癌的相关研究。

生物实验数据

生物活性 Flavokawain C is an orally active natural chalcone that inhibits the proliferation of multiple cancer cells and induces apoptosis (apoptosis) by upregulating GADD153 in cancer cells, inhibiting the phosphorylation of Akt and JNK, inhibiting early ERK phosphorylation, activating late ERK phosphorylation, activating caspase-related subtypes, inducing PARP-1 cleavage, inducing p21 and p27 upregulation, mutant p53 downregulation, and anti-apoptotic IAP protein downregulation, increasing intracellular ROS levels, and decreasing SOD activity, while downregulating FABP4, inducing cancer cell autophagy (autophagy), and activating the AMPK/mTOR pathway, reducing the expression of glycolysis-related proteins GLUT1 and HK2 to inhibit the glycolytic process in nasopharyngeal carcinoma cells, inhibiting the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and decreasing HSP90B1 expression, inhibiting angiogenesis by reducing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells, increasing intracellular γ-H2AX levels and inhibiting the phosphorylation of FAK, PI3K, and AKT in cells to induce DNA damage, exerting antitumor activity in multiple tumor xenograft mouse models, and is applicable to research related to colorectal cancer, colon adenocarcinoma, Wilms tumor, nasopharyngeal carcinoma, and liver cancer.
体外研究
(In Vitro)

Flavokawain C (60 μM; 6-48 h) 上调 HCT 116 细胞中内质网应激标志物 GADD153,抑制 Akt 的磷酸化,抑制早期 ERK 磷酸化、JNK 磷酸化的晚期,激活 ERK 磷酸化的晚期。
Flavokawain C (40-80 μM; 6-72 h) 降低 HT-29 细胞的活力,诱导凋亡形态学及细胞核变化,诱导 DNA 片段化,增加凋亡细胞比例,降低线粒体膜电位,,诱导细胞发生 G2/M 期细胞周期阻滞。
Flavokawain C (40-80 μM; 0-48 h) 在 HT-29 细胞中激活 caspase-3、-8 和 -9,诱导 PARP-1 裂解,诱导不依赖 p53 的 p21 和 p27 上调、突变型 p53 下调、内质网应激标志物 GADD153 上调,以及抗凋亡 IAP 蛋白 (XIAP、c-IAP1、c-IAP2) 下调,提高细胞内的 ROS 水平,降低 SOD 活性。
Flavokawain C (1-15 μM; 24-72 h) 抑制 G401 细胞的活力和增殖,抑制细胞的克隆形成能力,抑制细胞的迁移与侵袭。
Flavokawain C (1-10 μM; 0-24 h) 在 G401 细胞中可调控 EMT 标志物的表达,下调 FABP4,诱导完整的自噬流,并激活 AMPK/mTOR 通路。
Flavokawain C (0.5-4 μM; 48 h) 可抑制人鼻咽癌 HNE1 和 CNE2 细胞的增殖,提高细胞的凋亡率。
Flavokawain C (4 μM; 48 h) 可通过降低细胞外酸化速率、葡萄糖消耗及乳酸生成,降低糖酵解相关蛋白 GLUT1 和 HK2 的表达,抑制人鼻咽癌 HNE1 和 CNE2 细胞的糖酵解过程。
Flavokawain C (4 μM; 48 h) 可抑制人鼻咽癌 HNE1 和 CNE2 细胞中 EGFR/PI3K/Akt/mTOR 信号通路的激活,并降低 HSP90B1 的表达。
Flavokawain C (4 μM; 48 h) 在人鼻咽癌 HNE1 和 CNE2 细胞中可通过损伤人脐静脉内皮细胞 (HUVEC) 的管形成与迁移能力,降低人脐静脉内皮细胞 (HUVECs) 中血管生成蛋白 Ang-1 和 VEGF 的表达来抑制血管生成。
Flavokawain C (48 h) 可选择性抑制 Huh-7、Hep3B 和 HepG2 肝癌细胞的活力,其 IC50 值为 23.42 μM 至 30.71 μM;而对正常 MIHA 肝细胞的毒性较低,IC50 为 53.95 μM。
Flavokawain C (2.0-8.0 μM; 2 weeks) 抑制 Huh-7、Hep3B 和 HepG2 肝癌细胞的集落形成。
Flavokawain C (4.0-16.0 μM; 48 h) 抑制 Huh-7 和 Hep3B 肝癌细胞中的 DNA 复制,诱导细胞发生凋亡,下调细胞中抗凋亡蛋白 Bcl2 的表达,上调促凋亡蛋白 Bax 的表达,通过降低 Bcl2/Bax 比值来促进细胞凋亡。
Flavokawain C (4.0-16.0 μM; 48 h) 提高 Huh-7 和 Hep3B 细胞中 DNA 损伤应答标志物 γ-H2AX 的水平,抑制细胞中 FAK、PI3K 及 AKT 的磷酸化,诱导细胞发生 DNA 损伤。
Flavokawain C (4.0-16.0 μM; 48 h) 降低 Huh-7 和 Hep3B 细胞的细胞外基质黏附性,抑制细胞的迁移。

Western Blot Analysis

Cell Line: HCT 116 human colon carcinoma cells
Concentration: 60 μM
Incubation Time: 6, 12, 18, 24, 48 h
Result: Induced time-dependent upregulation of GADD153 protein levels.
Showed no GADD153 expression was detected in untreated control cells.\nCaused a transient increase in phosphorylated Akt levels at 6 hours.
Induced time-dependent decrease in phosphorylated Akt levels through 48 hours.
Showed no significant changes in total Akt protein levels were observed.\nCaused time-dependent decreases in phosphorylated ERK levels at 6, 12, and 18 hours.
Induced dramatic increases in phosphorylated ERK levels at 24 and 48 hours.
Showed total ERK levels remained unchanged.
Caused small reductions in phosphorylated JNK levels at 24 and 48 hours.
Showed no significant changes in total JNK, phosphorylated p38, or total p38 levels.

Cell Viability Assay

Cell Line: human colon adenocarcinoma HT-29 cells
Concentration: 40, 60, 80 μM
Incubation Time: 0, 6, 12, 24, 48, 72 h
Result: Reduced HT-29 cell viability in a dose- and time-dependent manner.
Decreased cell viability from 644.51% (control) to 185.17%, 111.81%, and 104.94% at 40, 60, and 80 μM respectively after 72 h.
Showed comparable inhibitory effect between 60 and 80 μM.

Apoptosis Analysis

Cell Line: human colon adenocarcinoma HT-29 cells
Concentration: 40, 60, 80 μM
Incubation Time: 48 h
Result: Induced dose-dependent apoptotic morphological changes, including cell shrinkage, surface blebbing, cytoplasmic vacuolation, chromatin condensation/fragmentation, and late apoptotic cells (pink fluorescence from propidium iodide staining).\nCaused a concentration-dependent increase in DNA fragmentation.
Increased TUNEL-positive cells to 11.6% at 80 μM relative to control.

Apoptosis Analysis

Cell Line: human colon adenocarcinoma HT-29 cells
Concentration: 40-80 μM
Incubation Time: 24-48 h
Result: Caused a dose- and time-dependent increase in Annexin V-FITC-positive apoptotic cells.

Cell Cycle Analysis

Cell Line: human colon adenocarcinoma HT-29 cells
Concentration: 40-80 μM
Incubation Time: 24-48 h
Result: At 24 h, dose-dependently increased G2/M phase cell population (with a small G1 phase accumulation) and decreased S phase population.
At 48 h, caused a marked dose-dependent increase in G2/M phase cell population, with the highest increase at 80 μM.

Cell Autophagy Assay

Cell Line: G401 nephroblastoma cells
Concentration: 10 μM
Incubation Time: 12 h
Result: Increased the number of both yellow (autophagosomes) and red (autolysosomes) puncta per cell compared to control, indicating enhanced autophagic initiation and maturation.

Immunofluorescence

Cell Line: Huh-7, Hep3B
Concentration: 4.0 μM, 8.0 μM, 16.0 μM
Incubation Time: 48 h
Result: Dose-dependently increased the number of 53BP1 foci (a marker of DNA damage response) in both cell lines.
Increased average 53BP1 foci per cell to >15 in both cell lines at 16.0 μM, compared to ~1.5 foci per cell in untreated controls.
体内研究
(In Vivo)

Flavokawain C (3 mg/kg;腹腔注射;每周 3 次;持续 4 周) 可抑制 BALB/c 裸鼠体内肾母细胞瘤异种移植物的生长,显著降低肿瘤体积与重量,而该效应可被 FABP4 过表达部分逆转。
Flavokawain C (3 mg/kg;腹腔注射;4 周 (皮下肿瘤模型);8 周 (肝转移模型)) 可在体内减小鼻咽癌皮下移植瘤的体积与重量,抑制肝转移,并下调糖酵解、血管生成及 EGFR/PI3K/Akt/mTOR 通路的激活;HSP90B1 敲低可增强其作用,而 HSP90B1 过表达则会逆转该作用。
Flavokawain C (16 mg/kg;腹腔注射;每日一次;连续 14 天) 可通过抑制肿瘤细胞增殖并诱导 DNA 损伤,显著抑制裸鼠体内 Huh-7 肝癌异种移植物的生长,且不会导致明显的体重下降。
Flavokawain C (1-3 mg/kg;腹腔注射;每周 3 次;持续 19 天) 可剂量依赖性地抑制 BALB/c 裸鼠体内 HCT 116 结肠癌异种移植物的生长,其中 3 mg/kg 剂量的肿瘤体积抑制率最高可达 52.17%;其作用机制为诱导细胞凋亡并降低细胞增殖活性,且不会引发显著的器官毒性。

Animal Model: BALB/c nude (5-week-old male, weight range 19.0g to 22.3g at euthanasia, subcutaneous nephroblastoma xenograft model)
Dosage: 3 mg/kg
Administration: i.p.; thrice weekly; 4 weeks
Result: Significantly reduced tumor volume and tumor weight compared to the control group.
Reduced expression of Ki67, FABP4, and Vimentin in tumor tissues.
Increased expression of E-cadherin in tumor tissues.
Induced loose tumor structure and increased inflammatory cell infiltration in tumor samples.
Had its tumor growth inhibition effect partially reversed by FABP4 overexpression.
Animal Model: BALB/C nude (male, 5-6 weeks old)
Dosage: 3 mg/kg
Administration: i.p.; 4 weeks (subcutaneous tumor model); 8 weeks (liver metastasis model)
Result: Reduced subcutaneous tumor volume and weight compared to vehicle control.
Downregulated the expression of HSP90B1, GLUT1, HK2, Ang-1, and VEGF in tumor tissues.
Inhibited the phosphorylation of EGFR, PI3K, Akt, and mTOR in tumor tissues.
Inhibited liver metastasis of NPC tumors, as measured by reduced bioluminescence signal from luciferase-expressing tumor cells.
Enhanced inhibitory effect on tumor growth and pathway suppression was observed with HSP90B1 knockdown.
Reversed inhibitory effect on tumor growth and pathway suppression was observed with HSP90B1 overexpression.
Animal Model: BALB/c nude mice (6-week-old)
Dosage: 16 mg/kg
Administration: i.p.; daily; 14 days
Result: Significantly reduced tumor growth rate, final tumor volume, and final tumor weight relative to controls.
Caused no significant changes in mouse body weight during treatment.
Induced cytoplasmic-nuclear separation and nuclear fragmentation (cell death) in tumor tissues via H&E staining.
Reduced Ki67 (proliferation marker) levels in treated tumor tissues.
Increased γ-H2AX (DNA damage marker) levels in treated tumor tissues.
Animal Model: BALB/c nude (female, 6 weeks old)
Dosage: 1 mg/kg; 3 mg/kg
Administration: i.p.; thrice weekly; 19 days
Result: Reduced final mean tumor volume to 658.19 mm3 (600% growth from initial 84.48 mm3) with 18.73-23.99% tumor volume inhibition (%T/C) over days 3-19 at 1 mg/kg.
Reduced final mean tumor volume to 411.31 mm3 (300% growth from initial 86.56 mm3) with 23.43-52.17% tumor volume inhibition (%T/C) over days 3-19 at 3 mg/kg.
Increased tumor necrotic area significantly (p < 0.05 vs control) at 3 mg/kg.
Increased TUNEL-positive cells significantly (p < 0.05 vs control) at 3 mg/kg.
Increased cleaved caspase-3 immunoreactivity score significantly (p < 0.05 vs control) at 3 mg/kg.
Decreased Ki67 immunoreactivity score significantly (p < 0.05 vs control) at 3 mg/kg.
Up-regulated Ig mu chain C region (secreted form) and down-regulated GRP78, hemopexin, kininogen-1, and apolipoprotein E compared to vehicle controls, with levels returning to near normal ranges at 3 mg/kg.
Caused no significant body weight loss in either dose group; kept serum liver (AST, ALT, ALP) and kidney (creatine, urea) function parameters within normal limits, with only mild urea elevation in the 1 mg/kg group; caused no pathological damage to major organs (heart, spleen, liver, lungs, kidneys).
性状 固体
颜色 Light yellow to orange

化学信息

分子量 300.31
分子式 C17H16O5
CAS No. 37308-75-1
别名 卡瓦胡椒素C

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.33 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 125 mg/mL (416.24 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.3299 mL16.6495 mL33.2989 mL83.2473 mL
5 mM0.6660 mL3.3299 mL6.6598 mL16.6495 mL
10 mM0.3330 mL1.6649 mL3.3299 mL8.3247 mL
15 mM0.2220 mL1.1100 mL2.2199 mL5.5498 mL
20 mM0.1665 mL0.8325 mL1.6649 mL4.1624 mL
25 mM0.1332 mL0.6660 mL1.3320 mL3.3299 mL
30 mM0.1110 mL0.5550 mL1.1100 mL2.7749 mL
40 mM0.0832 mL0.4162 mL0.8325 mL2.0812 mL
50 mM0.0666 mL0.3330 mL0.6660 mL1.6649 mL
60 mM0.0555 mL0.2775 mL0.5550 mL1.3875 mL
80 mM0.0416 mL0.2081 mL0.4162 mL1.0406 mL
100 mM0.0333 mL0.1665 mL0.3330 mL0.8325 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

卡瓦胡椒素C 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础